MARKET WIRETradingView • 21h ago
Evolus, Inc. Common Stock Estimates – NASDAQ:EOLSTradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
Why EOLS Stock dropped -2.58% Today — RQD Quant Desk Flash
$7.16 -2.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.11
Evolus Inc. (EOLS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $485.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EOLS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EOLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Evolus Inc. (NASDAQ: EOLS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $7.16 (-2.58% 1D, market cap $485.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EOLS ranks #905 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EOLS compare to FTH and AQST in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOLS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 66.3%, and ROIC of -35.0%. By comparison, FTH (Faeth Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $483.0M) and AQST (Aquestive Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $488.2M). Among the 5-stock peer group, EOLS leads on earnings multiple (N/A) while OVID leads on capital efficiency (-28.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EOLS?
▼
Per EOLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001570562), Evolus Inc. generated $297.2M in revenue (+11.6% YoY), -$51.6M in net income, and -$45.7M in free cash flow against $225.9M in total assets and $146.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.11 (-0.65%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EOLS)Realized 20D OHLCV Swing Band: ±9.2%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY EOLS SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (35% of score)
20D Institutional Volume Accumulation (±9.2% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)
FRED Regime × Technicals: 61% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.51-1.9% Next Q
34
Q2 (-2Q)Grade E$7.37+0% Next Q
31
Q3 (-1Q)Grade E$7.37-2.8% Next Q
29
CurrentGrade E$7.16-10.5% Hist 90D α
26
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EOLS Turnaround Squeeze
While EOLS currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.93) and Max Pain ($7.52) forces dealer call-delta covering toward $9.78.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EOLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EOLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EOLS Stock dropped -2.58% Today — RQD Quant Desk Flash
Evolus Inc. (EOLS) dropped -2.58% to $7.16, trading at 61% of its 52-week range ($3.86 – $9.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 61% of its 52-week range ($3.86 – $9.31) with RSI-14 at 46.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.2% around $7.16 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 66.3% gross margin and $0 annual free cash flow.
Live EOLS Headlines & Catalysts
MARKET WIREThe National Law Review • 1d ago
Bronstein, Gewirtz & Grossman, LLC Encourages Evolus, Inc. (EOLS)The National Law Review report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 1d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR Newswire report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
EOLS Q3'26 Earnings: revenue estimate is 77.58M USDTradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
(EOLS) and the Role of Price-Sensitive AllocationsStock Traders Daily report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
October 2026's Top Growth Stocks Backed By InsidersSimply Wall St report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Weekly Recap: Shares slip after action and Evolysse FDA decision due Q4'26TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
UTMD Trades at a Premium to the Industry: How to Play the Stock?TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 6d ago
Evolus to Participate in Upcoming Investor Conferences in New York and LondonNEWPORT BEACH, Calif., October 28, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team w
MARKET WIREYahoo • 13d ago
Evolus to Report Third Quarter Financial Results on November 4, 2026NEWPORT BEACH, Calif., October 21, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOLS)
- ✓Walkthrough of EOLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EOLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.32%🛡️ HOLDING TREND SUPPORT
2026-11-03O $7.52H $7.52L $7.16C $7.16VOL 794.4K
RES: $10.63SUP: $7.03SMA50: $7.93SMA200: $6.28
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EOLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on EOLS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EOLS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EOLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOLS)
Health Care Rank #905 of 1015
⚔️ FTH vs EOLS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EOLS vs. FTH, AQST, MPLT, OVID)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Evolus Inc. (EOLS) ranks #905 by composite RQD confidence (26/100, grade E) and #448 by equity capitalization ($485.5M). Within this direct 5-issuer industry benchmark cohort, EOLS leads on earnings valuation at N/A trailing P/E, while OVID leads on capital efficiency and profitability with -28.5% ROIC and — gross margin. OVID currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with EOLS at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EOLS
ACTIVE
Evolus Inc. | E | 26/100 | — | 66.3% | -35.0% | -2.58% | $485.5M | Benchmark Subject |
| FTH Faeth Therapeutics Inc. | E | 28/100 | — | — | -35.0% | +2.89% | $483.0M | /fth-vs-eols → |
| AQST Aquestive Therapeutics Inc. | E | 18/100 | — | 58.3% | -35.0% | -3.08% | $488.2M | /aqst-vs-eols → |
| MPLT MapLight Therapeutics Inc. | D- | 35/100 | — | — | -32.4% | -10.55% | $491.0M | /mplt-vs-eols → |
| OVID Ovid Therapeutics Inc. | D- | 40/100 | — | — | -28.5% | -5.91% | $496.1M | /ovid-vs-eols → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001570562 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Evolus Inc. (EOLS) reported GAAP revenue of $297.2M (+11.6% vs. FY2024 revenue of $266.3M , and +47.1% cumulative change since FY2023) , GAAP net income of -$51.6M, operating cash flow of -$42.3M, and free cash flow of -$45.7M (-134.7% YoY). On the balance sheet, EOLS closed FY2025 with $225.9M in total assets against $146.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $297.2M | -$51.6M | -$42.3M | -$45.7M | $225.9M | $146.1M |
| FY2024 (FY) | 2024-12-31 | $266.3M | -$50.4M | -$18.0M | -$19.5M | $232.6M | $121.5M |
| FY2023 (FY) | 2023-12-31 | $202.1M | -$61.7M | -$34.0M | -$34.0M | — | — |
3. EOLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EOLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Evolus Inc. (NASDAQ: EOLS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $7.16 (-2.58% 1D, market cap $485.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EOLS ranks #905 in composite RQD confidence.
How does EOLS compare to FTH and AQST in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOLS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 66.3%, and ROIC of -35.0%. By comparison, FTH (Faeth Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $483.0M) and AQST (Aquestive Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $488.2M). Among the 5-stock peer group, EOLS leads on earnings multiple (N/A) while OVID leads on capital efficiency (-28.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EOLS?
Per EOLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001570562), Evolus Inc. generated $297.2M in revenue (+11.6% YoY), -$51.6M in net income, and -$45.7M in free cash flow against $225.9M in total assets and $146.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EOLS trading relative to its 50-day, 200-day, and 52-week technical levels?
EOLS last traded at $7.16 (-2.58% on volume of 716,105 shares), positioning the stock -9.71% below its 50-day simple moving average ($7.93) and +14.01% above its 200-day simple moving average ($6.28). Across its 52-week range of $3.86 to $9.31, EOLS sits at the 60.6% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($6.50 to $7.82).
ROARABLE RATING BRIEF • RQD 26/100 (E)
✓ SEC XBRL & RQD VERIFIED
EOLS — Evolus Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Evolus Inc. (EOLS) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.16 (-2.58% 1D, market capitalization $485.5M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 66.3%, operating margin of -11.0%, and free cash flow yield of -9.20%.
- Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Evolus Inc. (EOLS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company generated revenue of $297.2M in FY 2025..5B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Evolus Inc. (EOLS) reported $297.2M in annual revenue (up from $266.3M in FY2024, +11.6% YoY) and -$51.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($202.1M revenue, -$61.7M net income) through FY2025, EOLS scaled operating cash flow to -$42.3M and free cash flow to -$45.7M, backed by $225.9M in total assets against $146.1M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.20% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $3.86 – $9.31 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector-level context provided is Health Care / Biotechnology: Pharmaceutical Preparations, with a beta of 1.0 per the market data. An investor should treat second-order ripple risk as unmapped rather than absent.
- Key Question #1: Can EOLS sustain or expand its -11.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $297.2M and free cash flow of -$45.7M, how will capital allocation balance growth reinvestment against $146.1M in total debt?
- Key Question #3: How sensitive is EOLS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
EOLS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Evolus Inc. (EOLS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 21h ago
Evolus, Inc. Common Stock Estimates – NASDAQ:EOLS TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The National Law Review • 1d ago
Bronstein, Gewirtz & Grossman, LLC Encourages Evolus, Inc. (EOLS) The National Law Review report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 1d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS PR Newswire report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
EOLS Q3'26 Earnings: revenue estimate is 77.58M USD TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
(EOLS) and the Role of Price-Sensitive Allocations Stock Traders Daily report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
October 2026's Top Growth Stocks Backed By Insiders Simply Wall St report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Weekly Recap: Shares slip after action and Evolysse FDA decision due Q4'26 TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
UTMD Trades at a Premium to the Industry: How to Play the Stock? TradingView report covering Evolus Inc. (EOLS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EOLS Bull vs. Bear Conversation Board — What's Your Call at $7.16?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EOLS 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $8.75 (+19.0%)
📌 Pinned Debate Gross margin of 66.3% and revenue growth from $202.1M to $297.2M show pricing power and top-line momentum that could support a margin r
Don't sleep on EOLS's setup in Health Care. Gross margin of 66.3% and revenue growth from $202.1M to $297.2M show pricing power and top-line momentum that could support a margin recovery.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (26/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
Both sides have a point here — EOLS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $6.25 (-15.0%)
Spot @ $7.35 An Altman Z-Score of 0.2, ROIC of -35%, and cash falling from $87.0M to $53.8M while debt rose to $146.1M signal acute forensic and liq
Sitting on the sidelines or leaning short EOLS above $7.35. An Altman Z-Score of 0.2, ROIC of -35%, and cash falling from $87.0M to $53.8M while debt rose to $146.1M signal acute forensic and liquidity risk.. Until Fundamental Cash Engine (2/20) and FCF yield (-9.2%) inflect higher, upside is capped near $9.31.